MDNews - Greater Kansas

Absorb is placed into the artery on a balloon at the end of a thin flexible tube. Absorb is expanded by inflating the balloon, pushing the plaque against the artery wall to enable greater blood flow. The balloon is removed, leaving Absorb to slowly release medication to the diseased area. With blood flow restored 1 , Absorb begins dissolving. Over time, Absorb dissolves into the blood vessel, which can remain open without support. 2 HOW ABSORB ™ WORKS For media use only For U.S. media, see Important Safety Information on the following page. INDICATIONS The Absorb GT1 Bioresorbable Vascular Sca-old (BVS) is a temporary sca-old that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm. ©2016 Abbott. All Rights Reserved. AP2942748 Rev. A 1 Absorb improves coronary luminal diameter, restores blood flow and enables movement of the treated vessel. Source: Absorb GT1 IFU. 2 Absorb dissolves except for two pairs of tiny metallic markers that remain in the artery to enable a physician to see where the device was placed. Source: Serruys PW et al. ABSORB Cohort B 5-Year. TCT 2015. Absorb is placed into the artery on a balloon at the end of a thin flexible tube. Absorb is expanded by inflating the balloon, pushing the plaque against the artery wall to enable greater blood flow. The balloon is removed, leaving Absorb to slowly release medication to the diseased area. With blood flow restored 1 , Absorb begins dissolving. Over time, Absorb dissolves into the blood vessel, which can remain open without support. 2 HOW ABSORB ™ WORKS For media use only For U.S. media, see Important Safety Information on the following page. INDICATIONS The Absorb GT1 Bioresorbable Vascular Sca-old (BVS) is a temporary sca-old that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm. ©2016 Abbott. All Rights Reserved. AP2942748 Rev. A 1 Absorb improves coronary luminal diameter, restores blood flow and enables movement of the treated vessel. Source: Absorb GT1 IFU. 2 Absorb dissolves except for two pairs of tiny metallic markers that remain in the artery to enable a physician to see where the device was placed. Source: Serruys PW et al. ABSORB Cohort B 5-Year. TCT 2015. 1 Absorb improves coronary luminal diameter, restores blood flow and enables movement of the treated vessel. Source: Absorb GT1 IFU. 2 Absorb dissolves except for two pairs of tiny metallic markers that remain in the artery to enable a physician to see where the device was placed. Source: Serruys PW et al. ABSORB Cohort B 5-Year. TCT 2015. Li ke traditiona l meta l stents, t he Absorb stent opens and expands the walls of blocked arteries, enabling better blood f low, and elutes everolimus to reduce inflammation and tissue growth at the treatment site inside the vessel; the drug is fully eluted in approximately six months. But unlike metallic stents, resorption of the Absorb stent begins about one year after implantation and is complete in approximately three years. "This a llows the patient's artery to regain its natural motion," says Dr. Chehab. "It also provides more options should the patient require future intervention." Absorb, which has wide applicability in a variety of patients, has been successfully used worldwide in a broad range of clini- cal situations, including single, long and calcified lesions; multivessel disease; unstable angina; and diabetes. It is now available in more than 100 countries and has been used to treat more than 150,000 patients worldwide. The first patient implant took place in 2006 in New Zealand as part of the initial ABSORB clinical study; the first U.S. patient implant took place six years later as part of ABSORB III. To f i n d a n A b s o rb - s t e nt- t ra i n e d cardiologist who does procedures at Via Christi, call 316-771-8116. For clinical information about the Absorb stent, go to dissolvingstent.com. ■ Three Phases of Healing + Revascularization (first six months after implantation): Vessel support and suppression of neointimal hyperplasia + Restoration (six–18 months after implantation): Transition to passive implant with start of resorption; formation of neointima + Resorption (18–36 months after implantation): Completion of resorption; vessel remodeling 1 1 M D N E W S . C O M /// M D N E W S G R E AT E R K A N S A S ■ D E C 2 016 /J A N 2 017

• Cover